Cryoport Future Growth
Future criteria checks 1/6
Cryoport is forecast to grow earnings and revenue by 34.5% and 9.6% per annum respectively. EPS is expected to grow by 36.6% per annum. Return on equity is forecast to be -11.8% in 3 years.
Key information
34.5%
Earnings growth rate
36.6%
EPS growth rate
| Life Sciences earnings growth | 16.8% |
| Revenue growth rate | 9.6% |
| Future return on equity | -11.8% |
| Analyst coverage | Good |
| Last updated | 29 May 2024 |
Recent future growth updates
Recent updates
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
Apr 15
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 15Cryoport Tanks On Chilling Results And Bad Decisions
Mar 14Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Mar 10Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)
Jan 15Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Oct 06Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term
Jul 23Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity
Jul 12Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Jun 13Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 06Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially
Nov 07Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Sep 23Cryoport: A Rare Investing Opportunity
Sep 22Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services
Sep 08Cryoport: Rapid Growth Is Great, But Shares Look Overpriced
Jul 30Cryoport: To Resume Aggressive Growth
May 11Cryoport: An Industry Leader Basking In Industry Tailwinds
Apr 15Cryoport: Risky Investment With Upside Potential
Apr 01Cryoport: More Growth Going Into New Year 2022
Dec 29Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?
Dec 05What Is Cryoport, Inc.'s (NASDAQ:CYRX) Share Price Doing?
Nov 09Is Cryoport (NASDAQ:CYRX) Using Too Much Debt?
Oct 17Cryoport: The Golden Stock
Oct 08Cryoport: Unfairly Punished, Valuation Update Shows 45% Upside
Oct 01Cryoport: Best Price-Positioned Medical Services Stock, As Seen By Market-Makers
Jul 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 295 | -52 | 13 | 26 | 5 |
| 12/31/2025 | 266 | -55 | -12 | 5 | 9 |
| 12/31/2024 | 243 | -69 | -45 | -22 | 10 |
| 3/31/2024 | 225 | -121 | -46 | -7 | N/A |
| 12/31/2023 | 233 | -108 | -46 | -1 | N/A |
| 9/30/2023 | 236 | -55 | -41 | 0 | N/A |
| 6/30/2023 | 241 | -47 | -32 | 3 | N/A |
| 3/31/2023 | 248 | -38 | -29 | 0 | N/A |
| 12/31/2022 | 237 | -45 | -26 | -2 | N/A |
| 9/30/2022 | 233 | -296 | -27 | -3 | N/A |
| 6/30/2022 | 230 | -297 | -23 | 5 | N/A |
| 3/31/2022 | 222 | -293 | -12 | 15 | N/A |
| 12/31/2021 | 223 | -284 | -17 | 8 | N/A |
| 9/30/2021 | 215 | -76 | -25 | -4 | N/A |
| 6/30/2021 | 169 | -78 | -32 | -18 | N/A |
| 3/31/2021 | 122 | -77 | -34 | -22 | N/A |
| 12/31/2020 | 79 | -75 | -25 | -15 | N/A |
| 9/30/2020 | 40 | -22 | -11 | -4 | N/A |
| 6/30/2020 | 38 | -23 | -6 | 0 | N/A |
| 3/31/2020 | 37 | -20 | -5 | 0 | N/A |
| 12/31/2019 | 34 | -18 | -7 | -1 | N/A |
| 9/30/2019 | 30 | -20 | -8 | -2 | N/A |
| 6/30/2019 | 26 | -9 | -7 | -2 | N/A |
| 3/31/2019 | 22 | -9 | -6 | -2 | N/A |
| 12/31/2018 | 20 | -10 | -6 | -3 | N/A |
| 9/30/2018 | 17 | -10 | -7 | -4 | N/A |
| 6/30/2018 | 15 | -9 | -6 | -5 | N/A |
| 3/31/2018 | 13 | -9 | -5 | -4 | N/A |
| 12/31/2017 | 12 | -8 | N/A | -4 | N/A |
| 9/30/2017 | 11 | -10 | N/A | -3 | N/A |
| 6/30/2017 | 10 | -10 | N/A | -4 | N/A |
| 3/31/2017 | 9 | -12 | N/A | -5 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -6 | N/A |
| 9/30/2016 | 7 | -12 | N/A | -6 | N/A |
| 6/30/2016 | 6 | -12 | N/A | -6 | N/A |
| 3/31/2016 | 6 | -15 | N/A | -6 | N/A |
| 12/31/2015 | 6 | -16 | N/A | -6 | N/A |
| 9/30/2015 | 5 | -15 | N/A | -5 | N/A |
| 6/30/2015 | 4 | -16 | N/A | -5 | N/A |
| 3/31/2015 | 4 | -12 | N/A | -4 | N/A |
| 12/31/2014 | 4 | -10 | N/A | -4 | N/A |
| 9/30/2014 | 3 | -10 | N/A | -4 | N/A |
| 6/30/2014 | 3 | -21 | N/A | -4 | N/A |
| 3/31/2014 | 3 | -20 | N/A | -4 | N/A |
| 12/31/2013 | 2 | -20 | N/A | -4 | N/A |
| 9/30/2013 | 2 | -20 | N/A | -4 | N/A |
| 6/30/2013 | 1 | -6 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYRX's revenue (9.6% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: CYRX's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CYRX is forecast to be unprofitable in 3 years.